Wave Life Sciences Ltd. — Director's Dealing 2026

Feb 28, 2026

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Wave Life Sciences Ltd. (WVE)
CIK: 0001631574
Period of Report: 2026-02-26

Reporting Person: Francis Chris (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2026-02-26	Ordinary Shares	M	17900	$3.87	Acquired	79767	Direct
2026-02-26	Ordinary Shares	S	17900	$15.094	Disposed	61867	Direct
2026-02-26	Ordinary Shares	M	15294	$4.75	Acquired	77161	Direct
2026-02-26	Ordinary Shares	S	15294	$15.00	Disposed	61867	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2026-02-26	Share Option (right to buy)	$3.87	M	17900	Disposed	2034-02-05	Ordinary Shares (17900)	Direct
2026-02-26	Share Option (right to buy)	$4.75	M	15294	Disposed	2033-02-17	Ordinary Shares (15294)	Direct

Footnotes

F1: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 5, 2025.

F2: The option vests as to 25% of the shares on February 5, 2025, and vests as to an additional 6.25% of the shares quarterly thereafter until February 5, 2028.

F3: The option vests as to 25% of the shares on February 17, 2024 and vests as to an additional 6.25% of the shares quarterly thereafter until February 17, 2027.

F4: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $15.00 to $15.10 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.